Canada markets open in 3 hours 15 minutes

Synairgen plc (SNG.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
5.13-0.04 (-0.77%)
As of 04:17PM GMT. Market open.

Synairgen plc

Mailpoint 810
Level F, South Block Southampton General Hospital Tremona Road
Southampton SO16 6YD
United Kingdom
44 23 8051 2800
https://www.synairgen.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard MarsdenCEO, MD & Executive Director328kN/A1967
Prof. Stephen T. Holgate CBE, M.D.Co-Founder, Non-Executive Director & Member of Scientific Advisory Board44kN/A1947
Dr. Phillip David MonkChairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director240kN/A1969
Prof. Donna DaviesCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Prof. Ratko DjukanovicCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Joseph Tregonning Colliver F.C.A.CFO & Executive DirectorN/AN/A1980
Dr. Gareth E. Walters Ph.D.Chief Regulatory OfficerN/AN/A1959
Ms. Jody BrookesSenior VP & Head of Clinical OperationsN/AN/AN/A
Mr. Richard FrancisSenior VP and Head of CMC & QualityN/AN/AN/A
Dr. Victoria TearHead of LaboratoryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Corporate Governance

Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.